Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + celecoxib + alpha-type-1 polarized dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Intraperitoneal, Oral, Intranodal, Intradermal
01
Overview
Cisplatin + celecoxib + DC vaccine is an investigational chemo-immunotherapy combination developed by Roswell Park Comprehensive Cancer Center for the treatment of advanced-stage ovarian cancer. The regimen consists of intraperitoneal cisplatin, a platinum-based DNA alkylating agent; oral celecoxib, a selective COX-2 inhibitor intended to modulate the tumor immune microenvironment; and an autologous alpha-type-1 polarized dendritic cell (alpha-DC1) vaccine. The vaccine is produced from patient-derived monocytes, pulsed with tumor lysate and keyhole limpet hemocyanin (KLH), and matured to induce a tumor-specific T-cell response. This combination is typically evaluated in a neoadjuvant setting alongside intravenous paclitaxel and may be further combined with chemokine modulatory agents like rintatolimod and interferon-alpha to enhance immune cell infiltration into the tumor.
- Other names
- cisplatin + celecoxib + DC vaccinealpha-DC1 vaccine + cisplatin + celecoxib
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNAHLA-A2-presented tumor blood vessel antigen peptide-MHC complexes
Beyond the preview
Go deeper on cisplatin + celecoxib + alpha-type-1 polarized dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + celecoxib + alpha-type-1 polarized dendritic cell vaccine.